BIM 23268

Drug Profile

BIM 23268

Alternative Names: BIM 23268D

Latest Information Update: 04 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biomeasure Inc
  • Class
  • Mechanism of Action Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 25 Aug 2003 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 03 Jun 2003 Beaufour-Ipsen is now called Ipsen
  • 12 Dec 2001 Preclinical development for Type-2 diabetes mellitus in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top